The Predictive Value of Clinical Data on Perioperative and Postoperative Risk Events in Patients With Head and Neck Artery Stenosis

Tang-Du Hospital1 site in 1 country1,500 target enrollmentDecember 1, 2022

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Postoperative Risk Factors for Patients With Carotid Artery Stenosis
Sponsor: Tang-Du Hospital
Enrollment: 1500
Locations: 1
Primary Endpoint: Recurrence of cerebral infarction
Status: Suspended
Last Updated: last year

Registry

clinicaltrials.gov

Start Date

December 1, 2022

End Date

December 31, 2026

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

Tang-Du Hospital

Responsible Party

Sponsor

•(1) All enrolled patients were diagnosed with clear head and neck artery stenosis and a risk event after head and neck revascularization;
•(2) Location of lesion: origin of internal carotid artery, bifurcation of internal and external carotid arteries;
•(3) Patients with symptomatic head and neck artery stenosis and dangerous events after head and neck blood flow reconstruction, and with a degree of stenosis ≥ 70% on non-invasive examination or stenosis ≥ 50% found on angiography;
•(4) Asymptomatic head and neck artery stenosis and risk events after head and neck revascularization, with a degree of stenosis ≥ 70% on non-invasive examination or stenosis ≥ 60% found on angiography;
•(5) Asymptomatic head and neck artery stenosis and dangerous events after head and neck blood flow reconstruction, with a non-invasive examination of stenosis degree less than 70%, but angiography or other examinations indicate that the stenosis lesion is in an unstable state;
•(6) Symptomatic head and neck artery stenosis and risk events after head and neck revascularization, non-invasive examination of head and neck artery stenosis and risk event degree after head and neck revascularization at 50% to 69%

•(1) Patients with poor overall condition and intolerance to general anesthesia;
•(2) Patients with mental illness or severe mental illness;
•(3) Severe respiratory system diseases;
•(4) Pregnant and lactating women;
•(5) Participating in another clinical study;
•(6) Patients with advanced tumors or those who are expected to die within one year;